Raptor Pharmaceutical Corp. (NASDAQ:RPTP)’s share price was down 2.4% on Thursday . The stock traded as low as $7.17 and last traded at $7.27, with a volume of 370,193 shares trading hands. The stock had previously closed at $7.45.

Several equities analysts recently weighed in on RPTP shares. Cowen and Company restated a “buy” rating and set a $8.00 target price on shares of Raptor Pharmaceutical Corp. in a report on Friday, August 19th. Zacks Investment Research upgraded shares of Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a report on Thursday, August 11th. Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Raptor Pharmaceutical Corp. in a report on Friday, May 6th. FBR & Co restated a “hold” rating and set a $10.00 target price on shares of Raptor Pharmaceutical Corp. in a report on Tuesday, August 23rd. Finally, Citigroup Inc. lowered shares of Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and lifted their target price for the company from $6.00 to $8.00 in a report on Monday, August 8th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $7.79.

The stock’s market cap is $617.62 million. The stock has a 50 day moving average of $6.58 and a 200-day moving average of $5.30.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The company earned $32.05 million during the quarter, compared to analyst estimates of $28.52 million. During the same quarter in the prior year, the company posted ($0.17) EPS. The firm’s quarterly revenue was up 37.4% compared to the same quarter last year. On average, analysts expect that Raptor Pharmaceutical Corp. will post ($0.91) earnings per share for the current fiscal year.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.